Do oncology researchers adhere to reproducible and transparent principles? A cross-sectional survey of published oncology literature.
cross-sectional study
oncology
replication crisis
reproducibility
transparency
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
31 12 2019
31 12 2019
Historique:
entrez:
2
1
2020
pubmed:
2
1
2020
medline:
1
12
2020
Statut:
epublish
Résumé
As much as 50%-90% of research is estimated to be irreproducible, costing upwards of $28 billion in USA alone. Reproducible research practices are essential to improving the reproducibility and transparency of biomedical research, such as including preregistering studies, publishing a protocol, making research data and metadata publicly available, and publishing in open access journals. Here we report an investigation of key reproducible or transparent research practices in the published oncology literature. We performed a cross-sectional analysis of a random sample of 300 oncology publications published from 2014 to 2018. We extracted key reproducibility and transparency characteristics in a duplicative fashion by blinded investigators using a pilot tested Google Form. The primary outcome of this investigation is the frequency of key reproducible or transparent research practices followed in published biomedical and clinical oncology literature. Of the 300 publications randomly sampled, 296 were analysed for reproducibility characteristics. Of these 296 publications, 194 contained empirical data that could be analysed for reproducible and transparent research practices. Raw data were available for nine studies (4.6%). Five publications (2.6%) provided a protocol. Despite our sample including 15 clinical trials and 7 systematic reviews/meta-analyses, only 7 included a preregistration statement. Less than 25% (65/194) of publications provided an author conflict of interest statement. We found that key reproducibility and transparency characteristics were absent from a random sample of published oncology publications. We recommend required preregistration for all eligible trials and systematic reviews, published protocols for all manuscripts, and deposition of raw data and metadata in public repositories.
Identifiants
pubmed: 31892667
pii: bmjopen-2019-033962
doi: 10.1136/bmjopen-2019-033962
pmc: PMC6955516
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e033962Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MV is funded through the US Department of Health and Human Services Office of Research Integrity and the Oklahoma Center for the Advancement of Science and Technology.
Références
Perspect Psychol Sci. 2016 Sep;11(5):702-712
pubmed: 27694465
Nature. 2012 Mar 28;483(7391):531-3
pubmed: 22460880
BMJ. 2005 May 7;330(7499):1057-8
pubmed: 15760970
PLoS Med. 2005 Aug;2(8):e124
pubmed: 16060722
PLoS Biol. 2019 Feb 21;17(2):e3000151
pubmed: 30789895
Mol Oncol. 2017 Dec;11(12):1661-1672
pubmed: 29024497
Cochrane Database Syst Rev. 2007 Apr 18;(2):MR000005
pubmed: 17443628
Ann Intensive Care. 2014 Jul 29;4:26
pubmed: 25114829
J Clin Epidemiol. 2013 Oct;66(10):1093-104
pubmed: 23958378
BMJ. 2008 Jun 28;336(7659):1472-4
pubmed: 18583680
PLoS One. 2018 Sep 12;13(9):e0202447
pubmed: 30208041
PLoS One. 2017 Jun 1;12(6):e0178379
pubmed: 28570573
JAMA. 2004 May 26;291(20):2457-65
pubmed: 15161896
Perspect Psychol Sci. 2012 Nov;7(6):645-54
pubmed: 26168125
PLoS Biol. 2018 Nov 20;16(11):e2006930
pubmed: 30457984
J Natl Cancer Inst. 1989 Jan 18;81(2):107-15
pubmed: 2642556
Nature. 2015 Oct 8;526(7572):182-5
pubmed: 26450039
JAMA Netw Open. 2019 May 3;2(5):e193684
pubmed: 31074821
Elife. 2014 Dec 10;3:null
pubmed: 25490932
JAMA. 2009 Sep 2;302(9):977-84
pubmed: 19724045
J Higher Educ. 2010 May 1;81(3):366-393
pubmed: 21132074
Nature. 2016 May 25;533(7604):452-4
pubmed: 27225100
Eur J Clin Invest. 2014 Sep;44(9):891-2
pubmed: 25041644
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
PLoS Comput Biol. 2016 Aug 04;12(8):e1005037
pubmed: 27490108
Evid Based Med. 2017 Aug;22(4):139-142
pubmed: 28701372
Lancet. 2009 Jul 4;374(9683):86-9
pubmed: 19525005
Trials. 2018 Feb 17;19(1):116
pubmed: 29454390
Nat Rev Drug Discov. 2011 Aug 31;10(9):712
pubmed: 21892149
PLoS One. 2015 Aug 05;10(8):e0132382
pubmed: 26244868
J Clin Oncol. 2012 Jan 10;30(2):210-6
pubmed: 22162583
PLoS Biol. 2016 Jan 04;14(1):e1002333
pubmed: 26726926
PLoS Biol. 2015 Jun 09;13(6):e1002165
pubmed: 26057340